Safety and Efficacy of Vesemnogene Lantuparvovec, an AAV-Based Gene Therapy in Young Children Under 24 Months with Spinal Muscular Atrophy in Low- and-Middle-Income Countries. Second Interim Report (August 2025).

Lock Hock Ngu[1,#], Qingling Mo[9,#], Shiqi Li[12,#], Teck Hock Toh[2], Jia Ni Lee[1], Kok Chong Lim[3], Edi Setiawan Tehuteru[4], Rahmi Lestari[5], Chinnuwat Sanguansermsri[6], Hany Abueita[7], Samson Gwer[8], Li Li[9], Zhuowei Wang[10], Salman Kirmani[11], Julia X. Chen[15], Yilia Y. Cai[15], Nanette N. Zheng[16], Yanqing Li[9], Qian Yang[9], Yanqiong Tang[9], Yeqing Li[9], Jason Z. Ye[14], Silk J. Shi[14], Jack F. Hong[14], Amy Y. Chen[14], Cole K. Zheng[14], Sanbin Wang[12,*], Teck-Onn Lim[13,*],Bruce T. Lahn[14,15,*], Austin T. Gao[16,*]

[1]Department of Clinical Genetics, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia
[2]Department of Paediatric & Clinical Research Centre, Sibu Hospital, Sarawak, Malaysia
[3]Columbia Asia Hospital, Kuala Lumpur, Malaysia
[4]Tzu Chi Hospital, Jakarta, Indonesia
[5]Dr Djamil Hospital, Padang, Indonesia
[6]Chiang Mai University Hospital, Chiang Mai, Thailand
[7]Palestine Medical Complex, Ramallah, Palestine
[8]Ubuntu Neurology, Nairobi, Kenya
[9]Kunming Hope Health Hospital, Kunming, Yunnan Province, China
[10]Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China
[11]Department of Medical Genetics, Aga Khan University, Karachi, Pakistan
[12]920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming, Yunnan Province, China
[13]ClinResearch SB, Kuala Lumpur, Malaysia
[14]VectorBuilder, Chicago, IL, USA
[15]Future Institute of Gene Delivery Research, Guangzhou, Guangdong Province, China
[16]Lantu Biopharma, Guangzhou, Guangdong Province, China

[#]These authors contributed equally.
*Correspondence: sanbin1011@163.com (SW); limteckonn@gmail.com (TOL); brucelahn@vectorbuilder.net (BTL); austingao@lantubiopharma.com (ATG)

Keywords
Gene therapy, AAV, vesemnogene lantuparvovec, spinal muscular atrophy

Abstract

Introduction
Spinal muscular atrophy (SMA) is a monogenic neuromuscular disorder due to survival motor neuron 1 mutation. Onasemnogene abeparvovec is a US FDA approved single-dose gene therapy for SMA, but is priced at USD 2.1 million per patient which severely limit its accessibility in low-and-middle-income countries (LMIC). We conducted a Phase 1 trial on vesemnogene lantuparvovec, an affordably priced substitute to onasemnogene intended for use in LMICs.

Methods
Sixteen patients with SMA (eight SMA Type 1 and Type 2 each) received a single dose of intrathecal vesemnogene lantuparvovec. Eleven patients received a low dose (1.5×10^{14} vg) and five received high dose (3.0×10^{14} vg). The primary outcomes were safety, and efficacy with the change from baseline in the developmental gross motor milestones achieved according to World Health Organization (WHO) criteria.

Results
As of the data cutoff in August 2025, 16 patients enrolled have been followed-up to at least three-month post-treatment. The median ages at diagnosis and dosing were 5 months (0.1, 18) and 12 months (3, 22), respectively. The commonest adverse event (AE) was transiently increased aspartate amino-transaminase which occurred in 11 patients (69%), with one patient having a level twice the upper limit of normal. No patient had required prolonged prednisolone prophylaxis. The most serious AEs were respiratory tract infections which occurred in four (50%) of eight patients with Type 1 SMA, leading to invasive ventilation in 2 and one of them eventually died.
Among the eight patients with SMA Type 1, two had gained one WHO milestone at 3-month post-treatment. Among the eight patients with SMA Type 2, at 3-month post treatment, all patients had gained at least one WHO milestone while 2 had gained four milestones and could walk with assistance.

Conclusions
In patients with Type 1 and Type 2 SMA below 24 months, a single intrathecal dose of vesemnogene lantuparvovec was safe and well-tolerated, resulting in improved developmental gross motor milestones which contrast with patients referred to the trial but were untreated. Further studies are necessary to confirm this gene therapy's long term safety and efficacy. (ClinicalTrials.gov number NCT06288230.)

Introduction

Spinal muscular atrophy (SMA) is a monogenic neuromuscular disorder due to mutation of the survival motor neuron 1 (SMN1) gene resulting in reduced SMN protein. SMA is a relatively common genetic disease (incidence 1 in 14694 newborns [1]). However it remains a leading cause of infant mortality, especially in low-and-middle-income countries (LMIC) despite the advent of disease-modifying drugs such as nusinersen and risdiplam which are costly lifelong treatments.

Onasemnogene abeparvovec is a single-dose gene therapy for SMA. It is particularly suitable for wider application in LMICs where the medical infrastructures to support life-long treatment are limited. It is remarkably effective in pre-symptomatic infants [2,3] and symptomatic infants less than six months of age [4-7]. Clinical benefits were observed up to age 24 months though its efficacy decreased when given to children with increasing age [8]. The latter is also attested by a recent trial of a single intrathecal dose of onasemnogene abeparvovec in older children up to five years of age [9].

Onasemnogene abeparvovec-xioi (Zolgensma, Novartis) has been approved by the US FDA since 2019 for treating SMA in pediatric patients less than 2 years of age. Unfortunately, it is priced at USD 2.1 million per patient [10], severely limiting its accessibility in LMIC. The availability of a more affordable substitute to onasemnogene will significantly mitigate the health burden posed by SMA in LMICs. Vesemnogene lantuparvovec, another adeno-associated virus (AAV) based gene therapy for SMA, was developed specifically for this purpose. To ensure its affordability in LMICs, vesemnogene will be priced close to its manufacturing costs, and the technology will be transferred at zero or minimal cost to individual LMICs who wish to adopt this to continue its development leading to local approval.

The vector construct of vesemnogene lantuparvovec is rAAV9.OEE.h-SMN1. Like onasemnogene abeparvovec-xioi, it is a nonreplicating, recombinant serotype 9 adeno-associated virus (rAAV9) containing a non-codon-optimized, full-length human survival motor neuron 1 transgene (rAAV9-SMN1) under the control of a promoter to restore functional SMN1 protein in motor neurones. The amino acid sequence of the SMN1 protein produced from the transgene is identical to that of normal wild-type hSMN1 protein. In vesemnogene lantuparvovec, the expression cassette flanked between inverted terminal repeats (ITR) sequences, comprises besides the transgene (human SMN1 cDNA), an optimized promoter, an engineered post-transcriptional regulatory element, and bovine growth hormone (BGH) polyadenylation (poly A) sequence. In onasemnogene abeparvovec-xioi the expression cassette consists of the chicken β-actin (CBA) promoter, simian virus 40 (SV40) intron and the BGH poly A sequence too.

Vesemnogene lantuparvovec is currently undergoing clinical trial (NCT06288230) in China and early access use outside China for patients unable to travel to China to be enrolled in the trial. We report here preliminary data on its safety and efficacy in children treated to date (August 2025).

Methods

We conducted a prospective, single arm ascending dose study at a single center in Kunming China. The study was conducted in accordance with the Declaration of Helsinki. The study site's institutional review-board (IRB) approved the protocol, and all parents or legal guardians gave written informed consent. Because of overwhelming demands for the study treatment, after preliminary safety and efficacy were observed, the study treatment was also made available under early access use in LMICs outside China. The study was registered under ClinicalTrials.gov (NCT06288230)

Study patients
Patients aged 24 months or younger who had genetically confirmed SMA (biallelic deletion of SMN1) without the genetic modifier (c.859G>C) [11] were enrolled into the study. They could be either symptomatic or presymptomatic. Exclusion criteria were contraindications for spinal tap procedure or administration of intrathecal therapy, elevated anti–AAV9 antibody titers >1:50 as determined by ELISA assay, use of invasive ventilatory support (tracheostomy with positive pressure) or non-invasive ventilatory support for 12 or more hours daily, severe joints contractures and/or scoliosis, active respiratory infection, active viral infection or other severe non–respiratory tract infection, abnormal liver function tests (alanine aminotransferase and aspartate aminotransferase more than twice the upper limit of normal) and other co-morbidities that in the opinion of the investigator may increase the risk of gene replacement therapy. Eligible patients were treated using one of two doses (low dose 1.5×10^{14} vg and high dose 3.0×10^{14} vg).

Study treatment
All patients received the study treatment as follows:
- Oral prophylactic prednisolone (1 mg/kg/day) starting one day prior to intrathecal vesemnogene lantuparvovec dosing and continuing for four weeks. Prednisolone dosing was then tapered off over 2 to 4 weeks if liver function test results were normal.
- A single intrathecal injection of vesemnogene lantuparvovec was given under sedation or anesthesia. Following administration, patients were placed in the Trendelenburg position for 15 minutes to enhance the distribution of the vector to cervical and brain regions. Patients were observed at the hospital for at least 48 hours prior to discharge.

Study assessments
Safety assessments consisted of monitoring adverse events (AE) and serious adverse events (SAE), monitoring hematology and blood chemistry results and physical examinations. Safety data were reported using the preferred terms of the Medical Dictionary for Regulatory Activities (MedDRA).
The primary efficacy outcome was the change from baseline in the developmental gross motor milestones achieved according to World Health Organization (WHO) criteria (sitting without support, standing with assistance, hands-and-knees crawling, walking with assistance, standing alone and walking alone) [12]. This outcome measure was captured on video and centrally reviewed. Secondary outcomes were change from baseline in body weight, requirements for non-invasive ventilation support and feeding support through a nasogastric tube or gastrostomy tube.

Statistical analysis
The safety and efficacy analyses were performed on an intention-to-treat basis, with all patients who had received a single dose of vesemnogene lantuparvovec included in the analyses. Results of efficacy analysis were reported as (1) change in the distribution of WHO motor milestones achieved at baseline and post-treatment, (2) change from baseline in WHO motor milestones post-treatment by individual patient (motor developmental trajectory), (3) highest WHO motor milestone achieved post-treatment by individual patient, (4) the proportion of patients who had gained one or more WHO motor milestone.

Results

The first patient was enrolled and treated in May 2024. After the first three patients were treated without overt safety signals, the trial enrolment was open to all LMICs. Between October 2024 and August 2025, we received a large number of referrals for enrolment. One hundred twenty-eight patients were screened and assessed for eligibility; 102 were ineligible because they had previously been referred for palliative care (N=16), were tested AAV antibody positive (N=4), or were aged above 24 months. There remained 26 eligible patients. We were constrained by the limited number of doses produced in the clinical trial batch. By August 2025, we could only treat 16 patients, while five had died awaiting treatment and another five patients remained on the wait list. All 16 treated patients had completed follow-up to 3-months post treatment, and none had withdrawn from the study.

Figure 1: Trial profile

Of the 16 treated patients, five were from Vietnam, four from Pakistan, two from Palestine, and one each from Malaysia, Thailand, Indonesia, India and Kenya. Table 1 shows the baseline characteristics of the patients. The median age at doing the study treatment was 12 months (range 3-22). Eight patients have two SMN2 copies, eight have three copies. Eight patients who have SMA type 1 were younger than 12 months at diagnosis with symptom onset before age six months and two copies SMN2 gene, another eight patients have SMA Type 2. Ten patients had received risdiplam treatment; none had Nusinersen.

At baseline, all patients could not sit unsupported except for three sitters and another was able to stand with assistance. All patients with SMA Type 1 were unable to sit unsupported except for one sitter. Among the eight babies with SMA Type 1, one had required feeding via nasogastric tube and another required feeding via gastronomy tube. No patient was on invasive ventilation though four had required intermittent non-invasive ventilatory support using a bilevel positive airway pressure machine (BiPAP) during previous episodes of respiratory infection. No patients with SMA Type 2 had required tube feeding or BiPAP.

Table 1: Baseline characteristics of patients

Baseline characteristics	All patients N=16	SMA Type 1 N=8	SMA Type 2 N=8	Low dose 1.5 × 10^{14} vg N=11	High dose 3.0 × 10^{14} vg N=5
Age at symptom onset, Median (range), months	4 (0.1,13)	3 (1, 4)	10 (0.1,13)	4 (1,12)	4 (0.1,13)
Age at diagnosis (confirmatory genetic test), Median (range), months	5 (0.1,18)	4 (1, 8)	11.5 (0.1,18)	8 (1,18)	4 (0.1,16)
Age at dosing Vesemnogene treatment, Median (range), months	12 (3,22)	8 (4, 20)	14.5 (3,22)	12 (4,20)	10 (3,22)
Sex, n (%) Female	12 (75%)	4 (50%)	8 (100%)	9 (81%)	3 (60%)
Family history (sibling) of SMA, n (%)	5 (31%)	3 (37%)	2 (25%)	4 (36%)	1 (20%)
Body weight, Median (range), Kg	8.1 (3.8, 10.1)	7.7 (4.9, 10.1)	8.6 (3.8, 10)	8.4 (4.9, 10.1)	7.4 (3.8, 8.7)
Number of SMN2 copy, n (%)					
1. Copy	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
2. Copies	8 (50%)	8 (100%)	0 (0%)	5 (45%)	3 (60%)
3. Copies	8 (50%)	0 (0%)	8 (100%)	6 (55%)	2 (40%)
Prior treatment with Risdiplam, n (%) Yes	10 (63%)	6 (75%)	4 (50%)	6 (55%)	4 (80%)
Feeding support, n (%) Yes	2 (12%)	2 (25%)	0 (0%)	2 (18%)	0 (0%)
Ever had Non-invasive ventilatory support (BiPAP), n (%) Yes	4 (25%)	4 (50%)	0 (0%)	3 (27%)	1 (20%)
WHO motor milestone prior to treatment					
0. Unable to sit without support	12 (75%)	7 (87%)	5 (62%)	9 (82%)	3 (60%)
1. Sitting without support	3 (19%)	1 (12%)	2 (25%)	1 (9%)	2 (40%)
2. Standing with assistance	1 (6%)	0 (0%)	1 (12%)	1 (9%)	0 (0%)
3. Hands-and-knees crawling	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
4. Walking with assistance	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
5. Standing alone	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
6. Walking alone	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

Percentages may not sum to 100% due to rounding.

Safety results

Thirty-three adverse events (AE) were reported in the trial to date, with 21 events occurring among patients with Type 1 SMA and 12 in Type 2 SMA.

Table 2 summarizes all the reported AE. The most common adverse event was increased aspartate aminotransferase (11 events, 69%), with one of them having more than twice the upper limit of normal. Other events were placement of nasogastric tube to prevent aspiration and/or for feeding support (5 events, 31%), increased alanine aminotransferase, lower respiratory tract infection, abnormal respiration (4 events, 25%), pyrexia, rash, respiratory failure (2 events each, 13%), increased blood Troponin I, leukocytosis, blood tested positive for mycoplasma pneumonia antibody (1 event each, 6%).

Increased aspartate aminotransferase and blood troponin I were reported as related to the study treatment. All increased aspartate aminotransferase events resolved spontaneously. All patients had received prednisolone prophylaxis; no patient had required prolonged prednisolone prophylaxis after the prescribed four weeks duration.

The SAEs were respiratory tract infections that occurred in four (50%) of eight patients with Type 1 SMA. These had led to hypoxemia requiring ventilatory support, two of whom had progressed to require invasive ventilation and one of whom died at 6-months post-treatment. These events were considered related to the natural history of Type 1 SMA. No patients with Type 2 SMA required any ventilatory support.

No child presented with signs or symptoms of thrombotic microangiopathy or sensory neuropathy, though electrophysiological testing was not conducted routinely in these young children.

Table 2: Incidence of treatment-emergent adverse events (TEAE) by MedDRA preferred terms

MedDRA Preferred term	All patients N=16	Low dose 1.5 × 10^{14} vg N=11	High dose** 3.0 × 10^{14} vg N=5
	N (%)	N (%)	N (%)
Any TEAE	33* (88%)	27* (91%)	6* (80%)
Pyrexia	2 (13%)	2 (18%)	0 (0%)
Rash	2 (13%)	2 (18%)	0 (0%)
Blood Mycoplasma pneumonia antibody positive	1 (6%)	1 (9%)	0 (0%)
Leukocytosis	1 (6%)	1 (9%)	0 (0%)
Respiratory tract infection	4 (25%)	4 (36%)	0**
Respiration abnormal	4 (25%)	4 (36%)	0**
Respiratory failure requiring invasive ventilation	2 (13%)	2 (18%)	0**
Feeding support/ nasogastric tube insertion	5 (31%)	5 (45%)	0**
Aspartate aminotransferase increased >ULN	11 (69%)	7 (64%)	4 (80%)
Aspartate aminotransferase increased >2x ULN	1 (6%)	0 (0%)	1 (20%)
Alanine aminotransferase increased >ULN	4 (25%)	2 (18%)	2 (40%)
Alanine aminotransferase increased >2x ULN	1 (6%)	0 (0%)	1 (20%)
Blood Troponin I increased	1 (6%)	1 (9%)	0 (0%)
Thrombocytopenia	0 (0%)	0 (0%)	0 (0%)
Dorsal root ganglia (DRG) inflammation	0 (0%)	0 (0%)	0 (0%)

Percentages may not sum to 100% due to rounding.
Abbreviation: MedDRA, Standardized Medical Dictionary for Regulatory Activities; TEAE, treatment-emergent adverse event; ULN, upper limit of normal.
*Sixteen adverse events occurred among 14 patients; some patients have more than one event while 2 had none at all.
**Safety data for patients on high dose observed to 1-month post treatment to date.

Efficacy results
All parents reported improvement in the motor function of their babies within days to weeks after vesemnogene therapy. Reported improvement in motor movement not previously observed in these babies were eyes and head able to follow moving objects, hand grasping object, holding head erect without support, rolling from back to sides, and vocalizing "papa, mama".

Table 3 shows the distribution of WHO motor milestones at baseline and achieved post-treatment. At 3-months post-treatment, all but 5 of the 16 patients (69%) had gained at least one WHO milestone, two with four WHO milestones and were able to walk with assistance.

Among the eight patients with SMA Type 1, only 2 had gained one WHO milestone at 3-months post-treatment (Table 4). Five (62%) had required nasogastric tube placement and four patients (50%) had required non-invasive ventilatory (NIV) support in the course of their respiratory infections, two (25%) of them had progressed to require invasive ventilation, one of them died at 6-month post-treatment.

Among the eight patients with SMA Type 2 at 3-month post treatment, all patients had gained at least one WHO milestone while two had gained four milestones and could walk with assistance (Table 4). No patients with Type 2 SMA had required any ventilatory or feeding support.

Table 5 compares the distribution of WHO motor milestones between patients treated using low dose of vesemnogene lantuparvovec (1.5 × 10^{14} vg) and high dose (3.0 × 10^{14} vg). At 3-month post treatment, there is no apparent difference in the distribution of WHO motor milestones achieved post-treatment between the two groups.

Table 3: WHO motor milestones at baseline and achieved post-treatment

WHO motor milestone	Baseline	1-month post-treatment	3-month post-treatment	6-month post-treatment
	N=16	N=16	N=16	N=8
Unable to sit	12 (75%)	8 (50%)	5(31%)	3 (37%)
Sitting without support	3 (19%)	6 (38%)	7 (44%)	2 (25%)
Standing with assistance	1 (6%)	1 (6%)	1 (6%)	1 (12%)
Crawling	0	1 (6%)	1 (6%)	-
Walking with assistance	0	0	2 (12%)	2 (25%)
Standing alone	0	0	0	-
Walking alone	0	0	0	-

Percentages may not sum to 100% due to rounding.

Figure 2: Trajectory of WHO motor milestones achieved post-treatment among the study patients.

Abbreviations: BL, baseline; M1, 1 month; M3, 3 months; M6, 6 months post-treatment.
WHO motor milestones: 0, Unable to sit; 1, Sitting without support; 2, Standing with assistance; 3, Crawling; 4, Walking with assistance; 5, Standing alone; 6, Walking alone. *, Child 1 died in M6.

Table 4: WHO motor milestones at baseline & achieved post-treatment by type of SMA

	SMA Type1				SMA Type2			
	Baseline	1-month post-treatment	3-month post-treatment	6-month post-treatment	Baseline	1-month post-treatment	3-month post-treatment	6-month post-treatment
WHO motor milestone	**N=8**	**N=8**	**N=8**	**N=4**	**N=8**	**N=8**	**N=8**	**N=4**
Unable to sit	7 (87%)	6 (75%)	5 (62%)	3 (75%)	5 (62%)	2 (25%)	0 (0%)	0 (0%)
Sitting without support	1 (12%)	2 (25%)	3 (37%)	1 (25%)	2 (25%)	4 (50%)	4 (50%)	1 (25%)
Standing with assistance	0	0	0	-	1 (12%)	1 (12%)	1 (12%)	1 (25%)
Crawling	0	0	0	-	0	1 (12%)	1 (12%)	-
Walking with assistance	0	0	0	-	0	0	2 (25%)	2 (50%)
Standing alone	0	0	0	-	0	0	0	-
Walking alone	0	0	0	-	0	0	0	-

Table 5: WHO motor milestones at baseline & achieved post-treatment by dosing level

	Low dose 1.5 × 10^{14} vg N=11				High dose 3.0 × 10^{14} vg N=5			
	Baseline	1-month post-treatment	3-month post-treatment	6-month post-treatment	Baseline	1-month post-treatment	3-month post-treatment	6-month post-treatment
WHO motor milestone	**N=11**	**N=11**	**N=11**	**N=8**	**N=5**	**N=5**	**N=5**	**-**
Unable to sit	9 (82%)	5 (45%)	3 (27%)	3 (37%)	3 (60%)	3 (60%)	2 (40%)	-
Sitting without support	1 (9%)	4 (36%)	4 (36%)	2 (25%)	2 (40%)	2 (40%)	3 (60%)	-
Standing with assistance	1 (9%)	1 (9%)	1 (9%)	1 (12%)	0	0	0	-
Crawling	0	1 (9%)	1 (9%)	-	0	0	0	-
Walking with assistance	0	0	2 (18%)	2 (25%)	0	0	0	-
Standing alone	0	0	0	-	0	0	0	-
Walking alone	0	0	0	-	0	0	0	-

Discussion

We conducted a Phase 1 study of vesemnogene lantuparvovec for treating children with SMA enrolled from diverse LMIC settings across populations and geographies.

Acute adverse events (AE) are expected to occur early from previous experience of AAV based gene therapy trials. The most concerning are immune-mediated toxicities associated with AAV, targeting in particular the liver and heart. Consistent with safety data from the use of AAV-based gene therapy for SMA, elevated transaminases occurred in the majority (75%) of patients within one month after receiving vesemnogene lantuparvovec. In contrast to the experience with onasemnogene abeparvovec administered intra-venously, elevated transaminases observed in this trial were isolated events without associated signs/symptoms

and the elevated levels resolved spontaneously in all patients. Only one patient had elevated aspartate and alanine transaminase at twice the normal upper limit which resolved within a week. No patient had required prolonged prednisolone prophylaxis. Increased blood troponin I occurred in only 1 patient. Like elevated transaminase, this was also an isolated event without associated signs and symptoms and the elevated levels resolved spontaneously. Overall, intrathecal administration of a single dose of vesemnogene lantuparvovec was safe and well-tolerated, consistent with the safety profile observed in the first trial of onasemnogene abeparvovec administered intrathecally [9].

On the efficacy of vesemnogene lantuparvovec, we have limited data on only 16 patients observed up to 3 to 6 months post treatment to date. All but 5 patients (69%) had gained at least one WHO milestone at 3-month post treatment. Remarkably, two patients had gained four WHO milestones in three months and were able to walk with assistance.

Nevertheless, this is a single-arm Phase 1 study. In the absence of a comparable control group, because of the possibility of confounding bias, it is not possible to infer whether the improved motor development is due to developmental maturation or to the effect of vesemnogene lantuparvovec.
- Randomized placebo control is ideal but was deemed ethically problematic even in LMIC setting where palliation is the standard of care for infants and toddlers with Type 1 SMA.
- It is also practically impossible to assemble a natural history cohort in this setting. Patients were enrolled from diverse LMIC settings with large variations in the local standard of care. In many LMICs, genetic tests for SMA are not available, infants with flaccid weakness and progressive respiratory failure are routinely referred to palliative care without genetic diagnosis of underlying disease, and there is variable access to charity-funded risdiplam among countries. Hence, patients referred for this trial are a highly selected population and constitute a fraction of all incident SMA by virtue of actually being diagnosed SMA, and 64% were treated with risdiplam.
- Patients most comparable to the treated patients in this trial are those who were enrolled but for various reasons were not treated. There are 2 such groups: (1) Patients with Type 1 SMA who were tested AAV antibody positive and therefore ineligible for trial. Of three such patients, two have progressed to respiratory failure requiring invasive ventilation within three months after referral for trial; (2) Patients with Type 1 SMA who were on wait list. Delay in getting to the study treatment was inevitable because parents and their doctors took time to consider the trial treatment option, delay in genetic and AAV antibody tests which require shipment of blood samples to the central lab, delay in obtaining passport/visa to travel to China to enter the trial. Of seven such patients, five had died within six months after referral for trial. The rapidly progressive adverse outcomes among these referred but untreated patents contrast with those treated in the trial. Further among the eight patients with SMA Type 2 given study treatment but were not at risk of respiratory failure or death, we observed uniform improvement in motor function within three months after vesemnogene treatment; all had gained at least one WHO milestone while one had gained four milestones and could walk with assistance. This finding is consistent with previous studies on AAV-based gene therapy which have shown rapid onset of action [4], even among patients who had prior disease modifying treatment [8]. Similar rapid and marked improvement have not been reported among patients on wait list including those on risdiplam.

This study has several limitations
- As mentioned above, the absence of a randomized control group and the use of external control raise the possibility of confounding bias. This is a problem common to all intervention studies in rare diseases when randomization is not practically or ethically feasible [13].

- The sample size is small for a Phase 1 study. Later phase studies will be initiated in LMICs to support local registration. The technology transfer of vesemnogene lantuparvovec to these LMICs is currently ongoing.
- The duration of observation to date is limited to three to six months after vesemnogene treatment. Longer-term safety and efficacy assessment will require observations on a larger sample of patients for longer duration.

In conclusion, this Phase 1 trial has provided preliminary evidence that the intrathecal administration of vesemnogene lantuparvovec, a novel AAV9-based gene therapy, is safe and also well-tolerated in young children with SMA Type 1 and Type 2 in LMIC settings. Despite the small cohort and limited follow-up duration, early post-treatment gains in WHO motor milestones, particularly in patients with Type 2 SMA, are promising. Importantly, these improvements were achieved in a population with limited access to standard-of-care therapies and in a setting where gene therapy has historically been inaccessible due to cost barriers. The absence of a randomized control group and the study population's heterogeneity limit the efficacy conclusions' strength. However, the stark contrast in the rapid progression and high mortality observed among untreated referred patients underscores the potential benefits of , vesemnogene lantuparvovec. These data reinforce the requirement for cost-efficient, scalable gene therapy solutions within LMICs as a priority matter. Further studies with larger sample size, extended follow-up, and locally contextualized registries are warranted to validate these findings and support regulatory approval and widespread adoption. The ongoing technology transfer and local manufacturing efforts are important steps towards sustainable SMA care and universal global access to innovative gene therapy.

References

1. Belter L, et al. Newborn Screening and Birth Prevalence for Spinal Muscular Atrophy in the US. JAMA Pediatr. 2024 Jul 15:e241911. doi: 10.1001/jamapediatrics.2024.1911.
2. Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type The Phase III SPR1NT trial, Nat Med>.2022; 1–9. 10.1038/s41591-022-01866-4..
3. Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, et al. Onasemnogene abeparvovec for presymp- tomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: The Phase III SPR1NT trial. Nat Med. 2022;1–8. 10.1038/s41591-022-01867-3.
4. Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy, N Engl J Med 2017;377(18):1713–22
5. Al-Zaidy SA, Kolb SJ, Lowes L, Alfano LN, Shell R, Church KR, et al. AVXS-101 (onasemnogene abeparvovec) for SMA Comparative study with a prospective natural history cohort, J Neuromuscul Dis 2019;6(3):307–17.
6. Day JW, Finkel RS, Chiriboga CA, Connolly AM, Crawford TO, Darras BT, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy with two copies of SMN2 (STR1VE): An open-label, single-arm, phase 3 study, Lancet Neurol 2021;20(4):284–93.
7. Mercuri E, Muntoni F, Baranello G, Masson R, Boespflug-Tanguy O, Bruno C, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): An open-label, single-arm, multicentre, phase 3 trial, Lancet Neurol 2021;20(10):832–41.
8. Weiß C, Ziegler A, Becker LL, Johannsen J, Brennenstuhl H, Schreiber G, Flotats-Bastardas M, Stoltenburg C, Hartmann H, Illsinger S, Denecke J, Pechmann A, Müller-Felber W, Vill K, Blaschek A, Smitka M, van der Stam L, Weiss K, Winter B, Goldhahn K, Plecko B, Horber V, Bernert G, Husain RA, Rauscher C, Trollmann R, Garbade SF,

Hahn A, von der Hagen M, Kaindl AM. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc Health. 2022 Jan;6(1):17-27. doi: 10.1016/S2352-4642(21)00287-X. Epub 2021 Oct 29. PMID: 34756190.

9. Finkel RS, Darras BT, Mendell JR, Day JW, Kuntz NL, Connolly AM, Zaidman CM, Crawford TO, Butterfield RJ, Shieh PB, Tennekoon G, Brandsema JF, Iannaccone ST, Shoffner J, Kavanagh S, Macek TA, Tauscher-Wisniewski S. Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (thecal). J Neuromuscul Dis. 2023;10(3):389-404. doi: 10.3233/JND-221560.

10. Buntz B. With prices topping $4 million, high stakes define cell and gene therapy landscape. Drug Discovery & Development 2024. Available at: https://www.drugdiscoverytrends.com/how-price-safety-and-efficacy-shape-the-cell-and-gene-therapy-landscape/

11. Prior TW, Krainer AR, Hua Y, Swoboda KJ, Snyder PC, Bridgeman SJ, et al. A positive modifier of spinal muscular atrophy in the SMN2 gene. Am J Hum Genet. 2009;85(3):408-13

12. WHO Motor Development Study: windows of achievement for six gross motor development milestones. Acta Paediatr. 2006;450:86-95

13. Gupta A, Hsu G, Kent S, Duffield SJ, Merinopoulou E, Lockhart A, Arora P, Ray J, Wilkinson S, Scheuer N, Ramagopalan SV, Groenwold RHH, Popat S, Hernán MA. Quantitative Bias Analysis for Single-Arm Trials With External Control Arms. JAMA Netw Open. 2025 Mar 3;8(3):e252152. doi: 10.1001/jamanetworkopen.2025.2152. PMID: 40136297; PMCID: PMC11947839